Literature DB >> 21123754

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.

S Kim1, S Swaminathan, L Shen, S L Risacher, K Nho, T Foroud, L M Shaw, J Q Trojanowski, S G Potkin, M J Huentelman, D W Craig, B M DeChairo, P S Aisen, R C Petersen, M W Weiner, A J Saykin.   

Abstract

OBJECTIVES: CSF levels of Aβ1-42, t-tau, and p-tau181p are potential early diagnostic markers for probable Alzheimer disease (AD). The influence of genetic variation on these markers has been investigated for candidate genes but not on a genome-wide basis. We report a genome-wide association study (GWAS) of CSF biomarkers (Aβ1-42, t-tau, p-tau181p, p-tau181p/Aβ1-42, and t-tau/Aβ1-42).
METHODS: A total of 374 non-Hispanic Caucasian participants in the Alzheimer's Disease Neuroimaging Initiative cohort with quality-controlled CSF and genotype data were included in this analysis. The main effect of single nucleotide polymorphisms (SNPs) under an additive genetic model was assessed on each of 5 CSF biomarkers. The p values of all SNPs for each CSF biomarker were adjusted for multiple comparisons by the Bonferroni method. We focused on SNPs with corrected p<0.01 (uncorrected p<3.10×10(-8)) and secondarily examined SNPs with uncorrected p values less than 10(-5) to identify potential candidates.
RESULTS: Four SNPs in the regions of the APOE, LOC100129500, TOMM40, and EPC2 genes reached genome-wide significance for associations with one or more CSF biomarkers. SNPs in CCDC134, ABCG2, SREBF2, and NFATC4, although not reaching genome-wide significance, were identified as potential candidates.
CONCLUSIONS: In addition to known candidate genes, APOE, TOMM40, and one hypothetical gene LOC100129500 partially overlapping APOE; one novel gene, EPC2, and several other interesting genes were associated with CSF biomarkers that are related to AD. These findings, especially the new EPC2 results, require replication in independent cohorts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123754      PMCID: PMC3030225          DOI: 10.1212/WNL.0b013e318204a397

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

Review 1.  Epigenetic dysregulation in cognitive disorders.

Authors:  Johannes Gräff; Isabelle M Mansuy
Journal:  Eur J Neurosci       Date:  2009-06-10       Impact factor: 3.386

2.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

Authors:  Alessia Maddalena; Andreas Papassotiropoulos; Britta Müller-Tillmanns; Hans H Jung; Thomas Hegi; Roger M Nitsch; Christoph Hock
Journal:  Arch Neurol       Date:  2003-09

3.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 4.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

5.  Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.

Authors:  Lynn M Bekris; Steven P Millard; Nichole M Galloway; Simona Vuletic; John J Albers; Ge Li; Douglas R Galasko; Charles DeCarli; Martin R Farlow; Chris M Clark; Joseph F Quinn; Jeffrey A Kaye; Gerard D Schellenberg; Debby Tsuang; Elaine R Peskind; Chang-En Yu
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

6.  Role of genes and environments for explaining Alzheimer disease.

Authors:  Margaret Gatz; Chandra A Reynolds; Laura Fratiglioni; Boo Johansson; James A Mortimer; Stig Berg; Amy Fiske; Nancy L Pedersen
Journal:  Arch Gen Psychiatry       Date:  2006-02

7.  The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype.

Authors:  Bregje W M van Bon; David A Koolen; Louise Brueton; Dominic McMullan; Klaske D Lichtenbelt; Lesley C Adès; Gregory Peters; Kate Gibson; Susan Moloney; Francesca Novara; Tiziano Pramparo; Bernardo Dalla Bernardina; Leonardo Zoccante; Umberto Balottin; Fausta Piazza; Vanna Pecile; Paolo Gasparini; Veronica Guerci; Marleen Kets; Rolph Pfundt; Arjan P de Brouwer; Joris A Veltman; Nicole de Leeuw; Meredith Wilson; Jayne Antony; Santina Reitano; Daniela Luciano; Marco Fichera; Corrado Romano; Han G Brunner; Orsetta Zuffardi; Bert B A de Vries
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

8.  The expression and functional characterization of ABCG2 in brain endothelial cells and vessels.

Authors:  Wandong Zhang; Jelena Mojsilovic-Petrovic; Moises F Andrade; Hong Zhang; Marguerite Ball; Danica B Stanimirovic
Journal:  FASEB J       Date:  2003-09-04       Impact factor: 5.191

9.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort.

Authors:  Li Shen; Sungeun Kim; Shannon L Risacher; Kwangsik Nho; Shanker Swaminathan; John D West; Tatiana Foroud; Nathan Pankratz; Jason H Moore; Chantel D Sloan; Matthew J Huentelman; David W Craig; Bryan M Dechairo; Steven G Potkin; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neuroimage       Date:  2010-01-25       Impact factor: 6.556

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  102 in total

Review 1.  Genome-wide significant, replicated and functional risk variants for Alzheimer's disease.

Authors:  Xiaoyun Guo; Wenying Qiu; Rolando Garcia-Milian; Xiandong Lin; Yong Zhang; Yuping Cao; Yunlong Tan; Zhiren Wang; Jing Shi; Jijun Wang; Dengtang Liu; Lisheng Song; Yifeng Xu; Xiaoping Wang; Na Liu; Tao Sun; Jianming Zheng; Justine Luo; Huihao Zhang; Jianying Xu; Longli Kang; Chao Ma; Kesheng Wang; Xingguang Luo
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

2.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 4.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

5.  HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group.

Authors:  Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

Review 6.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

7.  A Genome-Wide Association Study of α-Synuclein Levels in Cerebrospinal Fluid.

Authors:  Xiao-Ling Zhong; Jie-Qiong Li; Li Sun; Ya-Qing Li; Hui-Fu Wang; Xi-Peng Cao; Chen-Chen Tan; Ling Wang; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2018-06-29       Impact factor: 3.911

8.  Genetic modification of the relationship between phosphorylated tau and neurodegeneration.

Authors:  Timothy J Hohman; Mary Ellen I Koran; Tricia A Thornton-Wells
Journal:  Alzheimers Dement       Date:  2014-03-20       Impact factor: 21.566

9.  CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Authors:  Boris-Stephan Rauchmann; Thomas Schneider-Axmann; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

Review 10.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.